Entropy Technologies LP Acquires 8,570 Shares of DaVita Inc. $DVA

Entropy Technologies LP raised its position in shares of DaVita Inc. (NYSE:DVA) by 62.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 22,186 shares of the company’s stock after acquiring an additional 8,570 shares during the period. Entropy Technologies LP’s holdings in DaVita were worth $2,521,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of DVA. Elevation Wealth Partners LLC increased its position in DaVita by 147.3% during the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after acquiring an additional 165 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in DaVita during the second quarter valued at $43,000. Kestra Advisory Services LLC bought a new position in DaVita during the fourth quarter valued at $45,000. iSAM Funds UK Ltd bought a new position in DaVita during the third quarter valued at $46,000. Finally, Stance Capital LLC bought a new position in DaVita during the third quarter valued at $47,000. Institutional investors own 90.12% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the sale, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at $25,440,571.40. This represents a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. TD Cowen boosted their target price on shares of DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research note on Monday, May 11th. Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Deutsche Bank Aktiengesellschaft raised shares of DaVita from a “hold” rating to a “buy” rating and boosted their target price for the company from $126.00 to $220.00 in a research note on Wednesday, May 6th. Finally, Truist Financial boosted their target price on shares of DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a research note on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, DaVita currently has an average rating of “Hold” and an average price target of $199.17.

DaVita Price Performance

NYSE:DVA opened at $208.31 on Monday. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $211.80. The company has a 50-day moving average of $176.13 and a 200 day moving average of $146.28. The firm has a market cap of $13.37 billion, a PE ratio of 19.32, a price-to-earnings-growth ratio of 0.68 and a beta of 0.91.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The company had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.36 billion. During the same period in the prior year, the firm earned $2.00 earnings per share. The firm’s revenue for the quarter was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Sell-side analysts anticipate that DaVita Inc. will post 15.07 EPS for the current fiscal year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.